Researchers have developed a nasal vaccine targeting H5N1 bird flu that shows promising immune responses and protection, even with existing flu immunity.
Recent advancements in avian influenza research have led to the creation of a novel nasal vaccine aimed specifically at H5N1 bird flu. Identified in the U.S. in 2014, H5N1 has become a point of concern as it spreads from wild birds to farm animals and even humans, with over 70 reported human cases, including fatalities, in recent years. With the virus continuing to circulate among animal populations, experts caution that it could adapt and facilitate a human pandemic.
To combat the potential for widespread transmission, a team from Washington University School of Medicine in St. Louis has engineered a nasal vaccine that was tested on mice and hamsters. This intranasal delivery method produced strong immune responses and successfully prevented infection upon exposure to H5N1.
A prevalent issue with current flu vaccines is their reduced efficacy due to prior immune responses from seasonal flu infections. Notably, this nasal vaccine has shown impressive results, maintaining its effectiveness even in animals equipped with existing flu immunity.
Professor Jacco Boon, co-senior author of the study published in Cell Reports Medicine on January 30, expressed concern over the H5N1 strain's cross-species transmission, notably its recent infection of dairy cows in the U.S. He emphasized that this nasal vaccine could provide substantial protection by preventing initial respiratory infections.
The Limitations of Existing Vaccines
While traditional bird flu vaccines exist, they utilize outdated strains and have limited availability and effectiveness against current H5N1 variants. The research team built upon nasal vaccine technology established by Professor Michael S. Diamond and Dr. David T. Curiel at WashU Medicine to create a more effective immunization strategy.
A previously developed COVID-19 nasal vaccine using similar technology has shown promise, receiving clinical testing approval in the U.S. after its successful rollout in India.
Optimizing Immune Response
The success of this new vaccine hinges on the immune system’s ability to recognize the targeted virus rapidly. Boon and researcher Eva-Maria Strauch, an expert in antivirals and protein design, selected human-infecting H5N1 proteins to engineer an optimized antigen to elicit a robust immune response.
This antigen was incorporated into a harmless, non-replicating adenovirus, aligning with the strategy used for COVID-19 vaccines. The nasal vaccine demonstrated near-total protection against H5N1 in laboratory tests, surpassing the performance of intramuscular injections.
Even when administered in lower doses, the nasal vaccine was effective, particularly against heightened viral exposure. Its delivery method generates strong immune reactions throughout the body, especially in the nasal passages and respiratory tract, providing a significant edge over traditional injected vaccines. This localized immunity could prevent severe illness and reduce infection transmission.
As Diamond stated, targeting the upper airway where respiratory infections occur is pivotal for breaking the cycle of infection, not just for H5N1 but also for other flu strains.
Addressing Pre-Existing Immunity
In a critical aspect of their research, the team examined whether existing immunity from previous flu vaccines would diminish the effectiveness of the new H5N1 vaccine. They found that immunity did not hinder protection, which is vital given that most adults, rather than young children, possess memory from past flu exposures.
Looking ahead, the researchers aim to conduct additional testing in animal models and organoids that replicate human immune tissue. They're also focused on improving the vaccine to mitigate the impact of pre-existing flu immunity further and enhance antiviral responses.
This research was made possible through support from the Cooperative Center for Human Immunology and the Center for Research on Structural Biology of Infectious Diseases.
The Boon laboratory has received funding from Novavax, while Diamond's laboratory has unrelated funding support from various organizations. Such collaborations point toward continued advancements in vaccine technology that could play a critical role in addressing potential future pandemics.
For further details on this research and its implications, you can read more here.
Discussion
Sign in to join the discussion.